Conjugated estrogens and breast cancer risk

Gynecological Endocrinology

Volumn 13, Issue SUPPL. 6, 1999, Pages 13-19

  Campagnoli, C ^a,c   Ambroggio, S ^a   Biglia, N ^b   Sismondi, P ^b  

^a S ANNA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c NONE   (Italy)

Author keywords

Breast cancer; Conjugated estrogens; Equine estrogens; Insulin like growth factor I; Sex hormone binding globulin

Indexed keywords

ANDROGEN; CONJUGATED ESTROGEN; EQUILENIN; EQUILIN; ESTROGEN; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C;

BIOAVAILABILITY; BREAST CANCER; CANCER RISK; CELL PROLIFERATION; CONFERENCE PAPER; FEMALE; HUMAN; LIVER CELL; METABOLISM; PREMENOPAUSE; PRIORITY JOURNAL;

ADULT; AGED; BREAST NEOPLASMS; ESTRADIOL; ESTROGENS, CONJUGATED (USP); ESTRONE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; OBESITY; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN;

EID: 0033388481     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998;90: 814-23
2. Dahmoush L, Pike MC, Press MF. Hormones and breast-cell proliferation. In Lobo RA, ed. Treatment of the Postmenopausal Women: Basic and Clinical Aspects. New York: Raven Press, 1994:325-37
3. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative re-analysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-59
4. Kennedy DL, Baum C, Forbes MR. Noncontraceptive estrogens and progestins: use patterns over time. Obstet Gynecol 1985;65:441-6
5. Washburn SA, Honoré EK, Clinc JM, et al. Effects of 17α-dihydroequilenin sulfate on atherosclerotic male and female rhesus monkeys. Am J Obstet Gynecol 1996;175:341-51
6. Bhavnani BR. Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism. Proc Soc Exp Biol Med 1998;217:6-16
7. Fishman J, Osborne MP, Telang NT. The role of estrogen in mammary carcinogenesis. Ann NY Acad Sci 1995;768:91-100
8. Dey M. Components of conjugated estrogens: effects on the bone, the breast and the cardiovascular system. Presented at the International Symposium on Women's Health and Menopause, Milan, 1993; abstr. 37
9. Pujol P, Galtier-Dereure F, Bringer J. Obesity and breast cancer risk. Hum Reprod 1997; 12(Suppl): 116-25
10. Hankinson SE, Willett WC, Manson JE, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995;87:1297-302
11. Campagnoli C, Biglia N, Belforte P, et al. Post-menopausal breast cancer risk: oral estrogen treatment and abdominal obesity induce opposite changes in possibly important biological variables. Eur J Gynaecol Oncol 1992;13:139-54
12. Kaaks R. Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Control 1996;7:605-11
13. Kazer RR. Insulin resistance, insulin-like growth factor-I and breast cancer: a hypothesis. Int J Cancer 1995;62:403-9
14. Campagnoli C, Biglia N, Altare F, et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor-I, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol 1993;7:251-8
15. Campagnoli C, Biglia N, Peris C, et al. Potential impact on breast cancer risk of circulating insulin-like growth factor-I modifications induced by oral HRT in menopause. Gynecol Endocrinol 1995; 9:67-74
16. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351:1393-6
17. Westley BR, May FEB. Role of insulin-like growth factors in steroid modulated proliferation. J Steroid Biochem Mol Biol 1994;51:1-9
18. McGuire WL, Jackson JG, Figueroa JA, et al. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J Natl Cancer Inst 1992;84:1336-41
19. Lee AV, Weng CN, Jackson JG, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cell. J Endocrinol 1997;152:39-47
20. Campagnoli C, Ambroggio S, Biglia N, et al. Insulin-like growth factor-I and risk of breast cancer (letter). Lancet 1998;352:488-9
21. Carmina E, Lo Dico G, Carollo F, et al. Serum IGF-I and binding proteins 1 and 3 in post-menopausal women and the effects of estrogen. Menopause 1996;3:85-9
22. Helle SI, Omsjo IH, Cwyfan-Hughes SC, et al. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol 1996;45:727-32
23. Wren BG, Eden JA. Do progestogens reduce the risk of breast cancer? A review of the evidence. Menopause 1996;3:4-12
24. Pasqualini JR, Paris J, Sitruk-Ware R, et al. Progestins and breast cancer. J Steroid Biochem Mol Biol 1998;5:225-31
25. Musgrove EA, Sutherland RL. Steroidal control of cell proliferation in the breast and breast cancer. In Wren BG, ed. Progress in the Management of the Menopause. Carnforth, UK: Parthenon Publishing, 1997: 194-202
26. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963-9
27. Cline JM, Soderqvist G, von Schoultz E, et al. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat 1998;48:221-9
28. Goodman-Gruen D, Barrett-Connor E. Effect of replacement estrogen on insulin-like growth factor-I in postmenopausal women: the Rancho Bernardo Study. J Clin Endocrinol Metab 1996; 81:4268-71
29. Malarkey WB, Burleson M, Cacioppo JT, et al. Differential effects of estrogen and medroxyprogesterone on basal and stress-induced growth hormone release, IGF-I levels, and cellular immunity in postmenopausal women. Endocrine 1997;7: 227-33
30. Campagnoli C, Biglia N, Cantamessa C, et al. Effects of progestins on IGF-I serum level in estrogen-treated postmenopausal women. Zentralbl Gynäkol 1997;119 (Suppl):7-11